AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31974203 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-348 (Mitapivat)
Number of subjects: 15
Study 31974565 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of HLA-DRB5
Number of subjects: 10413
Study 31974565 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB*06:02
Number of subjects: 10413
Study 31974565 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQA*01:02
Number of subjects: 10413
Study 31974565 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01~DQA1*01:02~DQB1*06:02 haplotype
Number of subjects: 10413
Study 31974565 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01~DQA1*02:01~DQB1*03:03 haplotype
Number of subjects: 10413
Study 31974680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic modeling for primary tumors (PT)
Number of subjects: 0
Study 31974680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic modeling for metastatic lymph nodes (MLN)
Number of subjects: 0
Study 31975350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified human milk fortifier (HMF)
Number of subjects: 152
Study 31975350 — intervention group
Group type: COMPARATOR
Intervention: Non-acidified human milk fortifier (HMF)
Number of subjects: 152
Study 31975503 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week lower limb exercise programme
Number of subjects: 54
Study 31975539 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (Brief-IPQ)
Number of subjects: 213
Study 31975539 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of patient interviews
Number of subjects: 213
Study 31975781 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon-enhanced IMAGINE intervention (n=15)
Number of subjects: 23
Study 31975781 — intervention group
Group type: COMPARATOR
Intervention: Basic health education via email and blogs (Control group, n=8)
Number of subjects: 23
Study 31976385 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) with other interventions in Ethiopia
Number of subjects: 3
Study 31976385 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) alone or with mass media in Vietnam
Number of subjects: 3
Study 31976385 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-monthly IPC visits in Bangladesh and Ethiopia
Number of subjects: 3
Study 31976385 — intervention group
Group type: EXPERIMENTAL
Intervention: One IPC visit in Vietnam
Number of subjects: 3
Study 31977002 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (3 to 5 mg) administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal.
Number of subjects: 97
Study 31977002 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (3 to 5 mg) administered on intermittent 5/7-day schedule.
Number of subjects: 97
Study 31977002 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide in classifier-positive DLBCL patients (de novo).
Number of subjects: 97
Study 31977002 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide in classifier-negative DLBCL patients (de novo).
Number of subjects: 97
Study 31977005 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide
Number of subjects: 0
Study 31977005 — intervention group
Group type: COMPARATOR
Intervention: Classifier-negative patients
Number of subjects: 0
Study 31977016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frailty
Number of subjects: 2369
Study 31977016 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 2369
Study 31977454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reflux Symptom Questionnaire-electronic Diary (mRESQ-eD)
Number of subjects: 30
Study 31978210 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months.
Number of subjects: 22
Study 31978210 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg administered by IV infusion.
Number of subjects: 22
Study 31978221 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab (680 mg; 4 mL), administered subcutaneously once every 4 weeks
Number of subjects: 29
Study 31978886 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM-based therapy
Number of subjects: 37
Study 31978886 — intervention group
Group type: COMPARATOR
Intervention: Non-ROTEM group
Number of subjects: 37
Study 31980020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-1-8 wash-in scheme for sevoflurane LFA
Number of subjects: 199
Study 31980020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 199
Study 31980121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes technology use
Number of subjects: 0
Study 31980121 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines and educational material for clinicians and caregivers
Number of subjects: 0
Study 31980408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-free survival (MFS)
Number of subjects: 1207
Study 31980408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis development
Number of subjects: 1207
Study 31980466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician/patient decision
Number of subjects: 107
Study 31980466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 107
Study 31980497 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 31980497 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 31980830 — intervention group
Group type: EXPERIMENTAL
Intervention: Finetech Brindley Bladder System (FBBS) implantation without posterior rhizotomy
Number of subjects: 1
Study 31980868 — intervention group
Group type: EXPERIMENTAL
Intervention: cART-treated PLHIVs with microalbuminuria
Number of subjects: 30
Study 31980868 — intervention group
Group type: COMPARATOR
Intervention: cART-treated PLHIVs without microalbuminuria (controls)
Number of subjects: 30
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β in HFpEF
Number of subjects: 193
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β in HFrEF
Number of subjects: 193
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β after LVAD in HFrEF
Number of subjects: 193
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β after HTx in HFrEF
Number of subjects: 193
Study 31981321 — intervention group
Group type: COMPARATOR
Intervention: Circulating NRG1-β in healthy controls
Number of subjects: 193
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NRG1-β in HFrEF
Number of subjects: 193
Study 31981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of NRG1-β with outcomes in HFpEF
Number of subjects: 193
Study 31981731 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 31981731 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31981986 — intervention group
Group type: EXPERIMENTAL
Intervention: PTB/LBW babies
Number of subjects: 430
Study 31981986 — intervention group
Group type: COMPARATOR
Intervention: FTB/NBW babies
Number of subjects: 430
Study 31982162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BM-MNC treatment (5-7 days after AMI)
Number of subjects: 149
Study 31982162 — intervention group
Group type: EXPERIMENTAL
Intervention: Late BM-MNC treatment (3-4 weeks after AMI)
Number of subjects: 149
Study 31982162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 31982391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fluid volumes
Number of subjects: 637
Study 31982391 — intervention group
Group type: COMPARATOR
Intervention: Higher fluid volumes
Number of subjects: 637
Study 31982461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger (pre-lunch)
Number of subjects: 15
Study 31982461 — intervention group
Group type: COMPARATOR
Intervention: Satiety (post-lunch)
Number of subjects: 15
Study 31982461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood assessment
Number of subjects: 15
Study 31982610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic eradication therapy (EET) leading to complete eradication of intestinal metaplasia (CE-IM)
Number of subjects: 807
Study 31983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Born preterm
Number of subjects: 206
Study 31983307 — intervention group
Group type: COMPARATOR
Intervention: Born full-term
Number of subjects: 206
Study 31983322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis and percutaneous transluminal venoplasty
Number of subjects: 78
Study 31983321 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) based on CAD risk variants
Number of subjects: 1645
Study 31983496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rule-out pathway for myocardial infarction (postimplementation)
Number of subjects: 49
Study 31983496 — intervention group
Group type: COMPARATOR
Intervention: Standard care with hospital admission (preimplementation)
Number of subjects: 49
Study 31983637 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene-oriented images
Number of subjects: 2000
Study 31983637 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-oriented images
Number of subjects: 2000
Study 31983637 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing tasks with minimal memory load
Number of subjects: 2000
Study 31983669 — intervention group
Group type: EXPERIMENTAL
Intervention: High deep dyspareunia and BPFT
Number of subjects: 163
Study 31983669 — intervention group
Group type: COMPARATOR
Intervention: No or low deep dyspareunia
Number of subjects: 163
Study 31983669 — intervention group
Group type: COMPARATOR
Intervention: High deep dyspareunia but no BPFT
Number of subjects: 163
Study 31984235 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-c less than 70 mg/dL
Number of subjects: 3760
Study 31984235 — intervention group
Group type: COMPARATOR
Intervention: LDL-c of 100 ± 10 mg/dL
Number of subjects: 3760
Study 31984244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional doses of Yellow Fever vaccines
Number of subjects: 0
Study 31984244 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of Yellow Fever vaccines
Number of subjects: 0
Study 31984451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevanimibe HCl at doses ranging from 1.6 mg/kg/day to 158.5 mg/kg/day
Number of subjects: 63
Study 31984451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevanimibe HCl
Number of subjects: 63
Study 31984470 — intervention group
Group type: EXPERIMENTAL
Intervention: Infantile Tremor Syndrome (ITS)
Number of subjects: 92
Study 31984470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 31985097 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in self-efficacy at 6 months
Number of subjects: 201
Study 31985467 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 241
Study 31985803 — intervention group
Group type: EXPERIMENTAL
Intervention: High LVEF in women
Number of subjects: 4632
Study 31985803 — intervention group
Group type: COMPARATOR
Intervention: Normal LVEF in women
Number of subjects: 4632
Study 31985803 — intervention group
Group type: EXPERIMENTAL
Intervention: High LVEF in men
Number of subjects: 4632
Study 31985803 — intervention group
Group type: COMPARATOR
Intervention: Normal LVEF in men
Number of subjects: 4632
Study 31985868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score based on age >68 years, abnormal vital signs, impaired mobility, and decision to admit.
Number of subjects: 2949
Study 31985868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score indicating two or more predictors present.
Number of subjects: 2949
Study 31986140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox eflornithine combination therapy (NECT)
Number of subjects: 629
Study 31986169 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal scaling and root planing (SRP) treatment
Number of subjects: 15
Study 31986169 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without periodontitis)
Number of subjects: 15
Study 31986368 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) feeding protocol
Number of subjects: 439
Study 31986368 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-implementation stage)
Number of subjects: 439
Study 31987549 — intervention group
Group type: EXPERIMENTAL
Intervention: Head movement (motor task)
Number of subjects: 90
Study 31987725 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting physical activity guideline (≥60 min/d of moderate-to-vigorous PA)
Number of subjects: 342
Study 31987725 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting multiple guidelines (PA, sleep, and dietary)
Number of subjects: 342
Study 31987880 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk/short-distance group
Number of subjects: 0
Study 31987880 — intervention group
Group type: COMPARATOR
Intervention: Moderate-risk/long-distance group
Number of subjects: 0
Study 31987969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal photon radiation therapy (RT)
Number of subjects: 68
Study 31988143 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ICI-associated CAE cases (n=19, median TTO of 304 days)
Number of subjects: 19
Study 31988143 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ICI-associated CAE reports (n=159, median TTO 178 days)
Number of subjects: 19
Study 31988143 — intervention group
Group type: COMPARATOR
Intervention: Early CAE cases (n=19, median TTO of 14 days)
Number of subjects: 19
Study 31988143 — intervention group
Group type: COMPARATOR
Intervention: Early cases (n=437, median TTO 21 days)
Number of subjects: 19
Study 31988143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CAE cases (n=19) and late CAE cases (n=19)
Number of subjects: 19
Study 31988143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cases (n=437) and late cases (n=159)
Number of subjects: 19
Study 31988230 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate prescribing (PIP) at admission and discharge, assessed using the newest screening tool for older persons' potentially inappropriate prescriptions.
Number of subjects: 800
Study 31988230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug reactions (ADRs) during hospitalisation.
Number of subjects: 800
Study 31988230 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy, defined as the number of chronic prescribed medications.
Number of subjects: 800
Study 31988230 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity patterns identified using cluster analyses techniques.
Number of subjects: 800
Study 31988652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined abdominal/pelvic trauma
Number of subjects: 16359
Study 31988652 — intervention group
Group type: COMPARATOR
Intervention: Isolated pelvic fracture
Number of subjects: 16359
Study 31988972 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg twice daily
Number of subjects: 0
Study 31988972 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg once daily
Number of subjects: 0
Study 31989416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index
Number of subjects: 320
Study 31989416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index at threshold of 85
Number of subjects: 320
Study 31989416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index of 80-89
Number of subjects: 320
Study 31989725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Baclofen (ITB) therapy
Number of subjects: 1743
Study 31989731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lung disease (CLD) cases (FEV1 z-score <-1)
Number of subjects: 421
Study 31989731 — intervention group
Group type: COMPARATOR
Intervention: Control group (FEV1 z-score >0)
Number of subjects: 421
Study 31989731 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical covariates
Number of subjects: 421
Study 31989855 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon
Number of subjects: 0
Study 31989856 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stent (Eluvia Drug-Eluting Stent)
Number of subjects: 0
Study 31989925 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR5 receptor presence
Number of subjects: 0
Study 31989925 — intervention group
Group type: COMPARATOR
Intervention: Pollutants and bacterial proteins activating TLR4
Number of subjects: 0
Study 31990592 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the Lymphedema Functioning, Disability and Health Questionnaire (Lymph-ICF-UL)
Number of subjects: 50
Study 31990680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen-scavenging agents
Number of subjects: 0
Study 31990680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with shear wave elastography and FibroTest
Number of subjects: 0
Study 31990680 — intervention group
Group type: EXPERIMENTAL
Intervention: Helper-dependent adenovirus expressing Asl using a liver-specific (ApoE) promoter
Number of subjects: 0
Study 31990685 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 × 106 MICs per kg BW on day -2 (group A)
Number of subjects: 10
Study 31990685 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 × 108 MICs per kg BW on day -2 (group B)
Number of subjects: 10
Study 31990685 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 × 108 MICs per kg BW on day -7 (group C)
Number of subjects: 10
Study 31990685 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC treatment
Number of subjects: 10
Study 31991158 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 353
Study 31992108 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment sequences for advanced renal cell carcinoma
Number of subjects: 0
Study 31992179 — intervention group
Group type: EXPERIMENTAL
Intervention: VKA
Number of subjects: 1932
Study 31992179 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 1932
Study 31992179 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticoagulation)
Number of subjects: 1932
Study 31992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HNS) therapy
Number of subjects: 30
Study 31992396 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA control group
Number of subjects: 30
Study 31992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA (conservative therapy or observation)
Number of subjects: 30
Study 31992589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 102
Study 31992606 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-based care model comprising psychotherapy, medication management, family support/education, peer support, and vocational/educational support.
Number of subjects: 0
Study 31993016 — intervention group
Group type: EXPERIMENTAL
Intervention: Easily conducted tests during the first week post-stroke
Number of subjects: 0
Study 31993192 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 2)
Number of subjects: 20
Study 31993192 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 1)
Number of subjects: 20
Study 31993192 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (both pools)
Number of subjects: 20
Study 31993213 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Lifestyle-integrated Functional Exercise (gLiFE) programme
Number of subjects: 6
Study 31993275 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 30
Study 31993275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Gengigel)
Number of subjects: 30
Study 31993275 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal gel (Hiora SG)
Number of subjects: 30
Study 31993453 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag
Number of subjects: 440
Study 31993453 — intervention group
Group type: EXPERIMENTAL
Intervention: rMntC
Number of subjects: 440
Study 31993453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 31993561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic esophageal CONDUIT tool
Number of subjects: 188
Study 31993569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received counseling based on their step count)
Number of subjects: 135
Study 31993569 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded to their step activity)
Number of subjects: 135
Study 31993569 — intervention group
Group type: COMPARATOR
Intervention: No step-tracking device group
Number of subjects: 135
Study 31993578 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early ART
Number of subjects: 73
Study 31993746 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 31994009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 120
Study 31994009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31994009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 120
Study 31994250 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected mothers with varying CD4 counts and viral loads
Number of subjects: 164
Study 31994250 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration
Number of subjects: 164
Study 31994250 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CD4 count at birth
Number of subjects: 164
Study 31994250 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral load
Number of subjects: 164
Study 31994361 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 882
Study 31994361 — intervention group
Group type: COMPARATOR
Intervention: Non-digoxin
Number of subjects: 882
Study 31994788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir
Number of subjects: 103